Compound · Triple GIP/GLP-1/glucagon agonist

TRISIGNAL

Agonista triple GIP/GLP-1/Glucagón

FormatSignalis Bio lyophilized vial with 12 mg declared content, made in the United States and designated research grade.

TRISIGNAL · Signalis Bio

What science explores · not a promise

  • Metabolic signaling
  • Energy balance
  • Liver metabolism

What it is

TRISIGNAL is a research-grade triple GIP/GLP-1/glucagon agonist by Signalis Bio. This synthetic peptide is designed to interact with three receptors involved in metabolic signaling. Activity at GIP and GLP-1 receptors is investigated in relation to satiety signals and glucose-dependent insulin secretion. Activity at the glucagon receptor extends research questions toward energy expenditure and liver metabolism. Its structure includes chemical modifications that change its properties compared with the natural peptides used as reference molecules. Studying three receptor systems also requires distinguishing the contribution of each pathway from their combined activity.

This material is research grade and is not a medicine. Published observations depend on the experimental system and its controls; they are not a promise for people. Documentation of identity, purity, and origin must be evaluated independently of any scientific hypothesis or proposed biological mechanism.

Origin

This is a synthetic molecule, not an extract from human tissue. Its design belongs to metabolic research programs developed in industrial laboratories during the twenty-first century. Clinical studies published in 2023 expanded interest in this class of triple agonists. The Signalis Bio product belongs to a catalog of research materials.

How it is studied

Researchers use cells with defined receptors, animal models, and clinical studies of triple agonism. They measure receptor activation, intracellular signals, glucose, body composition, and liver fat through imaging. Comparisons across systems explore the contribution of each receptor without assuming that a cellular signal represents a clinical change. These studies make no promises of personal effects. Available human information has limitations and does not amount to evidence for this commercial batch. Interpretation requires reviewing controls, reproducibility, analytical identity, and differences between models before drawing scientific conclusions about the observations.

Related lessons

Related readings

Dr. Peptide is a virtual presenter created with artificial intelligence; she is not a healthcare professional. This content is educational and is not medical advice, diagnosis or treatment. Decisions about your health belong with a licensed professional. Research-grade products; sale to adults 18+ only.

Follow us on Instagram · @Signalisbio